Pharmacokinetic characteristics and morphometric effects of sodium-glucose contransporter-2 inhibitors in men and women with type 2 diabetes mellitus (literature review and own results)
| Autor: | O.V. Prybyla |
|---|---|
| Jazyk: | English<br />Ukrainian |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Mìžnarodnij Endokrinologìčnij Žurnal, Vol 17, Iss 4, Pp 293-303 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2224-0721 2307-1427 |
| DOI: | 10.22141/2224-0721.17.4.2021.237342 |
| Popis: | Background. According to the latest international clinical guidelines, gliflozins — sodium-glucose cotransporter-2 inhibitors — are indicated as oral antidiabetic drugs of second-third-line therapy in type 2 diabetes mellitus. Due to insulin-independent stimulation of glucosuria, gliflozins have extraglycemic effects such as weight loss, improved adipose tissue distribution, better plasma lipid profile, and decreased uricemia that in generally reduce the risk of cardiovascular complications. The purpose of this study was to evaluate the effectiveness of dapagliflozin in the treatment of men and women with type 2 diabetes mellitus with a metabolically unhealthy phenotype. Materials and methods. The study included 17 individuals with diabetes mellitus type 2 (11 men and 6 women), aged 58.0 ± 1.7 years (95% confidence interval 53–62), whose body composition was evaluated by bioelectric impedance using a Tanita analyzer BC-545N (Japan). Patients received therapy with dapagliflozin, antihypertensive and antihyperlipidemic drugs (statins). Results. A three-month use of dapagliflozin in a dose of 10 mg once daily caused a decrease in body mass index, waist circumference, improvement of body composition, in particular a reduction in total body fat (the significance of changes was determined using a paired t-test). No significant changes in muscle and bone mass, body composition, lipid profile, and uricemia level were observed. The group of women, in contrast to men, had a decreased level of visceral fat, which was accompanied by an improvement in the body’s water supply, and a reduction in the estimated metabolic age. Conclusions. Treatment of type 2 diabetes patients with sodium-glucose cotransporter-2 inhibitors for 3 months has reduced the degree of obesity and improved some indices of body composition. Confirmation of this trend can be obtained in further observations. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|